Madhu Kumar
Stock Analyst at Goldman Sachs
(2.86)
# 1,498
Out of 5,182 analysts
142
Total ratings
55.1%
Success rate
19.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $186.95 | -1.04% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $8.04 | -25.37% | 8 | Jan 26, 2024 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $7.71 | +120.49% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $2.41 | +65.98% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $260.95 | -40.60% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $66.73 | -20.58% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $11.23 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $61.03 | +19.61% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $40.41 | +248.92% | 9 | Apr 14, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $34 | $25.15 | +35.19% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $3.43 | +74.93% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $8.03 | +74.35% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $33.33 | -85.00% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.67 | +199.63% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $10.85 | +720.28% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $8.18 | +1,367.89% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $13.13 | +547.37% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $3.41 | +1,043.70% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $17.16 | +232.17% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.48 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $0.72 | +125,703.75% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $9.06 | +120.75% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $4.47 | +2,137.14% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $50.01 | -30.01% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $13.40 | +198.51% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $29.09 | +1,632.55% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $318.85 | -27.87% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $19.40 | +5,698.97% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.92 | +4,245.94% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $33.53 | -35.88% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $49.51 | -52.53% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $186.95
Upside: -1.04%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $8.04
Upside: -25.37%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $7.71
Upside: +120.49%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $2.41
Upside: +65.98%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $260.95
Upside: -40.60%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $66.73
Upside: -20.58%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $11.23
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $61.03
Upside: +19.61%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $40.41
Upside: +248.92%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $25.15
Upside: +35.19%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $3.43
Upside: +74.93%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $8.03
Upside: +74.35%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $33.33
Upside: -85.00%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.67
Upside: +199.63%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $10.85
Upside: +720.28%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $8.18
Upside: +1,367.89%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $13.13
Upside: +547.37%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $3.41
Upside: +1,043.70%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $17.16
Upside: +232.17%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.48
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $0.72
Upside: +125,703.75%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $9.06
Upside: +120.75%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $4.47
Upside: +2,137.14%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $50.01
Upside: -30.01%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $13.40
Upside: +198.51%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $29.09
Upside: +1,632.55%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $318.85
Upside: -27.87%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $19.40
Upside: +5,698.97%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $0.92
Upside: +4,245.94%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $33.53
Upside: -35.88%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $49.51
Upside: -52.53%